DrugPatentWatch Database Preview

Pfizer Company Profile

Email this page to a colleague

PFIZER has one hundred and thirty-five approved drugs.

There are thirty-six US patents protecting PFIZER drugs. There is one tentative approval on PFIZER drugs.

There are seven hundred and sixty-four patent family members on PFIZER drugs in seventy-one countries and one hundred and forty-four supplementary protection certificates in seventeen countries.

International Patents:	764
US Patents:	36
Tradenames:	102
Ingredients:	96
NDAs:	135
Drug Master File Entries:	3
Patent Litigation for Pfizer:	See patent lawsuits for Pfizer
PTAB Cases with Pfizer as petitioner:	See PTAB cases with Pfizer as petitioner

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer Inc	TROXYCA ER	naltrexone hydrochloride; oxycodone hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	207621-004	Aug 19, 2016		DISCN	No	No	8,685,443	Start Trial				Start Trial
Pfizer Inc	LORBRENA	lorlatinib	TABLET;ORAL	210868-002	Nov 2, 2018		RX	Yes	Yes	8,680,111	Start Trial	Y	Y		Start Trial
Pfizer	PROCARDIA XL	nifedipine	TABLET, EXTENDED RELEASE;ORAL	019684-003	Sep 6, 1989	AB2	RX	Yes	Yes		Start Trial				Start Trial
Pfizer Inc	IBRANCE	palbociclib	CAPSULE;ORAL	207103-002	Feb 3, 2015		RX	Yes	No	RE47739	Start Trial	Y	Y		Start Trial
Pfizer	TAO	troleandomycin	CAPSULE;ORAL	050336-002	Approved Prior to Jan 1, 1982		DISCN	No	No		Start Trial				Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pfizer	LIPITOR	atorvastatin calcium	TABLET;ORAL	020702-004	Apr 7, 2000	RE40667*PED	Start Trial
Pfizer Pharms	NEURONTIN	gabapentin	TABLET;ORAL	020882-002	Oct 9, 1998	4,087,544*PED	Start Trial
Pfizer Pharms	REZULIN	troglitazone	TABLET;ORAL	020720-001	Jan 29, 1997	6,046,202	Start Trial
Pfizer	DIFLUCAN	fluconazole	TABLET;ORAL	019949-003	Jan 29, 1990	4,416,682	Start Trial
Pfizer	GEODON	ziprasidone mesylate	INJECTABLE;INTRAMUSCULAR	020919-001	Jun 21, 2002	6,110,918	Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Tablets	25 mg and 50 mg	➤ Subscribe	2004-11-19
➤ Subscribe	Tablets	20 mg and 40 mg	➤ Subscribe	2010-03-29
➤ Subscribe	Sublingual Tablets	0.6 mg	➤ Subscribe	2011-12-29
➤ Subscribe	Capsules	5 mg and 10 mg	➤ Subscribe	2005-06-21
➤ Subscribe	For Injection	500 mg/vial	➤ Subscribe	2011-06-17
➤ Subscribe	Extended-release Tablets	4 mg and 8 mg	➤ Subscribe	2012-10-31
➤ Subscribe	Tablets	5 mg/80 mg	➤ Subscribe	2009-04-07
➤ Subscribe	Capsules	75 mg, 100 mg and 125 mg	➤ Subscribe	2019-02-04
➤ Subscribe	Extended-release Tablets	11 mg	➤ Subscribe	2016-11-07
➤ Subscribe	Tablets	100 mg	➤ Subscribe	2004-10-25
➤ Subscribe	Sublingual Tablets	0.3 mg, 0.4 mg and 0.6 mg	➤ Subscribe	2005-10-19
➤ Subscribe	Capsules	20 mg, 40 mg, 60 mg and 80 mg	➤ Subscribe	2005-02-07
➤ Subscribe	Capsules	0.125 mg, 0.25 mg, and 0.5 mg	➤ Subscribe	2014-05-01
➤ Subscribe	Tablets	150 mg and 200 mg	➤ Subscribe	2005-11-09
➤ Subscribe	Tablets	5 mg/10 mg, 5 mg/20 mg, 5 mg/40 mg, 10 mg/10 mg, 10 mg/20 mg and 10 mg/80 mg	➤ Subscribe	2006-12-29
➤ Subscribe	Tablets	2.5 mg/40 mg	➤ Subscribe	2009-09-17
➤ Subscribe	Injection	20 mg/mL, 2 mL and 5 mL vials	➤ Subscribe	2004-07-26

Subscribe to access the full database, or Start Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1077912	SPC/GB07/053	United Kingdom	Start Trial	SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB07/053 GRANTED TO SCHWARZ PHARMA AG IN RESPECT OF THE PRODUCT FESOTERODINE AND ITS SALTS WITH PHYSIOLOGICALLY ACCEPTABLE ACIDS, INCLUDING FUMARIC ACID, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6299 DATED 10 FEBRUARY 2010 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 23 APRIL 2022.
1230209	PA2007008	Lithuania	Start Trial	PRODUCT NAME: FESOTERODINUM; REGISTRATION NO/DATE: EU/1/07/386/001 - EU/1/07/386/010 20070420
1003503	05C0048	France	Start Trial	PRODUCT NAME: AMLODIPINE OU UN DE SES SELS D?ADDITION D?ACIDES PHARMACAUTIQUEMENT ACCEPTABLES/ ATORVASTATINE OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE IN FRANCE: NL 29929 DU 20050707; REGISTRATION NO/DATE AT EEC: NL 29929 DU 20050707
2822953	301006	Netherlands	Start Trial	PRODUCT NAME: LORLATINIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/19/1355 20190508
0473687	3/1999	Austria	Start Trial	PRODUCT NAME: FOSPHENYTOIN-NATRIUM; NAT. REGISTRATION NO/DATE: 1-22664 19980728; FIRST REGISTRATION: GB 00019/0157 19980204
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.